Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (3): 361-363    DOI: 10.31083/j.ejgo.2020.03.5376
Original Research Previous articles | Next articles
Ten-year survival in patients with endometrial adenoacanthoma and endometrial adenocarcinoma with malignant squamous cell differentiation
U. Indraccolo1(), R. Martinello1, G. Scutiero1, G. Bernardi1, 2, C. Borghi1, O. Brasile1, 2, P. Greco1, 2
1Department of Reproduction and Growth, Obstetric and Gynaecology Unit, Azienda Ospedaliero-Universitaria Arcispedale Sant'Anna of Cona, Italy
2Department of Morphology, Surgery and Experimental Medicine, Section of Obstetric and Gynaecology, University of Ferrara, Ferrara 06024, Italy
Download:  PDF(241KB)  ( 193 ) Full text   ( 3 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Objectives: It is acknowledged that squamous differentiation in the endometrial adenocarcinoma does not affect the outcome of type I cancer. However, it has been recently reported that the so-called shadow cell differentiation is likely present in endometrial adenoacanthomas. As the shadow cells differentiation suggests a caspase-independent cell death, based on the previous reports it can be hypothesized that the endometrial adenoacanthoma would have a better prognosis than the endometrial adenocarcinoma with squamous differentiation. Methods: From a database of 829 endometrial cancer, 34 endometrial adenoacanthomas and 18 endometrial adenocarcinomas with malignant squamous differentiation were assessed. The Kaplan-Meier curves were generated and compared for endometrial adenoacanthomas and endometrial adenocarcinomas with malignant squamous differentiation. Results: the 10-year survival in patients with adenocarcinoma with malignant squamous differentiation is significantly lower than the survival in patients with adenoacanthoma. Advanced stage (2009 FIGO II or over) was more likely found in adenocarcinoma with malignant squamous differentiation at the surgery time. Matching groups for the FIGO stage, there were no difference in overall survival. Conclusion: patients with endometrial adenoacanthoma have a better prognosis than patients with endometrial adenocarcinoma with malignant squamous differentiation probably because of the earlier stage diagnosis.

Key words:  Endometrial adenocarcinoma      Adenoacanthoma      Squamous cells differentiation     
Submitted:  30 September 2019      Accepted:  24 October 2019      Published:  15 June 2020     
*Corresponding Author(s):  U. Indraccolo     E-mail:  ugo.indraccolo@libero.it

Cite this article: 

U. Indraccolo, R. Martinello, G. Scutiero, G. Bernardi, C. Borghi, O. Brasile, P. Greco. Ten-year survival in patients with endometrial adenoacanthoma and endometrial adenocarcinoma with malignant squamous cell differentiation. European Journal of Gynaecological Oncology, 2020, 41(3): 361-363.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.03.5376     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I3/361

Figure 1.  - Survival curves with 95% confidence intervals. Time variable (on x-axis) is expressed in semesters.

Table 1  - Descriptive statistics and univariate comparisons.
Adenoacanthoma Adenocarcinoma with malignant squamous cells differentiation p
Age 61.4 64.5 0.424
FIGO 2009 Stage
-II+ 1 (2.9%) 7 (38.9%) 0.003
-Ia 9 (26.5%) 2 (11.1%) 0.351
-Ib 24 (70.6%) 9 (50.0%) 0.244
Grading
-Grade 1 12 (35.3%) 4 (22.2%) 0.512
-Grade 2 17 (50.0%) 11 (61.1%) 0.637
-Grade 3 5 (14.7%) 3 (16.7%) 0.768
Radicality on parametria
-Yes 0 1 (5.6%) 0.272
Lymphadenectomy
-Yes 4 (11.85) 5 (27.8%) 0.143
Adjuvant chemotherapy
-Yes 15 (44.1%) 8 (44.4%) 0.625
Adjuvant radiotherapy
-Yes 12 (35.3%) 4 (22.2%) 0.259
[1] De Palo G., Kenda R., Andreola S., Luciani L., Musumeci R., Rilke F.: “Endomatrial carcinoma: stage I. A retrospective analysis of 262 patients”. Obstet. Gynecol., 1982, 60, 225.
pmid: 7155485
[2] Demopoulos R.I., Dubin N., Noumoff J., Blaustein A., Sommers G.M.: “Prognostic significance of squamous differentiation in stage I endometrial adenocarcinoma”. Obstet. Gynecol., 1986, 68, 245.
pmid: 3737041
[3] Zainio R.J., Kurman R.J.: “Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma”. Semin. Diagn. Pathol., 1988, 5, 154.
pmid: 3041509
[4] Abeler V.M., Kiørstad K.E., Berle E.: “Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population”. Int. J. Gynecol. Cancer., 1992, 2, 9.
doi: 10.1046/j.1525-1438.1992.02010009.x pmid: 11576230
[5] Behbakht K., Yordan E.L., Casey C., DeGeest K., Massad L.S., Kirschner C.V., et al.: “Prognostic indicators of survival in advanced endometrial cancer”. Gynecol. Oncol., 1994, 55 (3 Pt 1), 363.
[6] Zainio R.J., Kurman R., Herbold D., Gliedman J., Bundy B.N., Voet R., et al.: “The significance of squamous differentiation in endometrial carcinoma. Data from a Gynecologic Oncology Group study”. Cancer., 1991, 68, 2293.
pmid: 1913465
[7] SGO Clinical Practice Endometrial Cancer Working Group., Burke W.M., Orr J., Leitao M., Salom E., Gehrig P., Olawaiye A.B.: et al.; Society of Gynecologic Oncology Clinical Practice Committee.: “Endometrial cancer: a review and current management strategies: part I”. Gynecol. Oncol., 2014, 134, 385.
doi: 10.1016/j.ygyno.2014.05.018 pmid: 24905773
[8] Colombo N., Creutzberg C., Amant F., Bosse T., González Martín A., Ledermann J., et al.; ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group.: “ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up”. Int. J. Gynecol. Cancer., 2016, 26, 2.
doi: 10.1097/IGC.0000000000000609 pmid: 26645990
[9] Pekin T., Yildizhan B., Eren F., Pekin O., Yildizhan R.: “Adenocarcinoma, adenoacanthoma, and mixed adenosquamous carcinoma of the endometrium”. Eur. J. Gynaecol. Oncol., 2001, 22, 151.
pmid: 11446483
[10] Nakamura T.: “Shadow cell differentiation from squamoid morule in endometrial adenoacanthoma”. Int. J. Clin. Exp. Pathol., 2015, 8, 13120.
pmid: 26722510
[11] Nakamura T.: “Shadow cell differentiation: a comparative analysis of modes of cell death with apoptosis and epidermal/trichilemmal keratinization”. Dermatopathology. (Basel)., 2018, 5, 86.
[12] Greco P., Martinello R., Indraccolo U., Borghi C., Bonaccorsi G., Scutiero G.: “Outcome of endometrial cancer after lymphadenectomy: a single center retrospective analysis with long-lasting follow-up”. Minerva. Ginecol., 2017, 69, 405.
doi: 10.23736/S0026-4784.17.04028-X pmid: 28398020
[13] Pecorelli S.: “Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium”. Int. J. Gynaecol. Obstet., 2009, 105, 103.
doi: 10.1016/j.ijgo.2009.02.012 pmid: 19367689
[1] Y. Xiong, Y.Y. Xiong, Z.G. Xu. Detection of high-risk human papillomavirus DNA and immunohistochemical expressions of p16, vimentin, ER, and PR in primary endocervical and endometrial adenocarcinomas[J]. European Journal of Gynaecological Oncology, 2016, 37(4): 517-521.
[2] M.E. Sak, I. Alanbay, A. Rodriguez, T. Gokaslan, M. Borahay, I. Shureiqi, G.S. Kilic. The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 36-40.
No Suggested Reading articles found!